Caroline Speers

Caroline Speers

Auto-generated profile, based on publicly available information

Caroline Speers

BC Cancer Agency, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ANAlan M. Nichol
Alan M. Nichol
ECElisa K. Chan
Elisa K. Chan
SLSarah Lucas
Sarah Lucas
SSSally L. Smith
Sally L. Smith
LGLovedeep Gondara
Lovedeep Gondara
STScott Tyldesley
Scott Tyldesley

1 March 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
DODawn Owen
Dawn Owen
STScott Tyldesley
Scott Tyldesley
CACheryl Alexander
Cheryl Alexander
CSCaroline Speers
Caroline Speers
PTPauline Truong
Pauline Truong
EWElaine S. Wai
Elaine S. Wai

1 September 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
LHLindsay Hedden
Lindsay Hedden
HKHagen Kennecke
Hagen Kennecke
DVDiego Villa
Diego Villa
KJKarrisa Johnston
Karrisa Johnston
CSCaroline Speers
Caroline Speers
Stuart PeacockStuart Peacock
Stuart Peacock

1 January 2019 in Journal of Geriatric Oncology
Verified
Journal Article
Closed access
TRTyler Raycraft
Tyler Raycraft
WCWinson Y. Cheung
Winson Y. Cheung
YYYaling Yin
Yaling Yin
CSCaroline Speers
Caroline Speers
JKJenny J. Ko
Jenny J. Ko
CMCaroline Mariano
Caroline Mariano

1 November 2013 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
IKIrene Karam
Irene Karam
MLMaria F. Lesperance
Maria F. Lesperance
TBTanya Berrang
Tanya Berrang
CSCaroline Speers
Caroline Speers
STScott Tyldesley
Scott Tyldesley
PTPauline T. Truong
Pauline T. Truong

1 April 2013 in Current Oncology
Verified
Journal Article
Open access
APAna Lohmann Palhares
Ana Lohmann Palhares
CSC.H. Speers
C.H. Speers
Stephen ChiaStephen Chia
Stephen Chia
Background: Altered formulations of taxanes may lack cross-resistance with standardly used solvent-based taxanes. The primary objective of the present study was to assess the clinical benefit of nanoparticle albumin-bound (nab)–paclitaxel in women with metastatic breast cancer previously treated with and without adjuvant taxane in British Columbia. Methods: The BC Cancer Agency Pharmacy data repository and Breast Cancer Outcomes Unit database were linked to identify all patients who received nab-paclitaxel in British Columbia since its introduction in 2007. Hormone receptor status, demographic characteristics, number of cycles prescribed, and time to treatment failure were extracted and analyzed. Results: From 2007 to 2011, 138 patients in British Columbia received nab-paclitaxel, with 122 patients available for analysis. Most (70.5%) received adjuvant chemotherapy; about a quarter (24.6%) received an adjuvant taxane. Patients who received adjuvant taxane were more likely to have node-positive (86.7% vs. 48.9%, p = 0.007), estrogen receptor–negative (46.7% vs. 13.0% p < 0.001) disease and to receive initial adjuvant radiotherapy (76.7% vs. 51.1%, p < 0.001). For the entire cohort, the median number of nab-paclitaxel cycles prescribed was 4.4 (range: 0.3–13). The median number of nab-paclitaxel cycles was greater when that agent was given as first- or second-line therapy than as third-line or greater therapy (5.0 cycles vs. 3.7 cycles respectively). The median time to treatment failure was 96 days in the prior adjuvant taxane group (range: 0–361) and 73.5 days in the no prior adjuvant taxane group (range: 0–1176). Conclusions: This retrospective study demonstrates potential clinical activity of nab-paclitaxel in metastatic breast cancer regardless of whether patients had prior exposure to adjuvant taxanes.